Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SCNX · NASDAQ · Pharmaceutical Preparations
Scienture Holdings (SCNX) · oqro.io/stocks/SCNX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.28−0.1571 (−6.45%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Scienture Holdings was filed in the last 90 days. The latest on record was on Aug 25, 2022.
Since 2017, Scienture Holdings insiders reported 4 open-market purchases and 21 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2022.
No open-market sale by an insider of Scienture Holdings (SCNX) was filed with the SEC in the last 90 days.
No trade in Scienture Holdings (SCNX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−83.7% (−$11.67) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $13.95 on Nov 20, 2025 to $2.28 on Nov 20, 2026 (−83.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Commack, Ny.
Last 12 months
−83.7%
Market value
$93.5M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 117K shares sold short (0.3% of shares outstanding), +10.8% vs the previous count, 3.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$1.25M
+112.6% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $4.75M, at Sep 30, 2026
Net income, last 12 months
−$40.4M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 19, 2026.
Revenue, fiscal 2025
$432K
+215.9% vs the year before
Net income, fiscal 2025
−$41.5M
A loss for the year
Shares outstanding
41.1M
As of Aug 13, 2026
In fiscal 2024 the company spent $14.9M on dividends. Cash actually paid, from its cash-flow statement.
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No Schedule 13D or 13G filing on SCNX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Scienture Holdings reported 4 open-market purchases and 21 sales since 2017; purchases in 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $130M4×4 trades | — |
| 2021 | — | $41K3×3 trades |
| 2020 | — | $97K6×6 trades |
| 2019 | — | $3.3K5×5 trades |
| 2018 | — | $1492×2 trades |
| 2017 | — | $28.1B5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Off-exchange trading: 57.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.9% on ATS, 52.5% with other brokers), close to its 2-week average of 57.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (15.3%), MS RPOOL (ATS-6) (7.8%), LEVEL ATS (7.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
On July 25, 2024, we acquired a wholly-owned subsidiary, Scienture LLC. Scienture LLC is a specialty pharmaceutical company focused on the commercialization and development of products for the treatment of Cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders. Scienture LLC’s mission is to bring to market innovative technology-based products to address unmet medical needs.
And 11 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Notice of delisting or failure to meet listing rules
8-K on sec.govTop officer leaving
“Resignation of Eric Sherb On May 26, 2026, Eric Sherb, the Chief Financial Officer (“CFO”) of Scienture Holdings, Inc.”
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Latest annual report filed Mar 30, 2026, compared with the one filed Mar 26, 2025. Read the filing
In the ordinary course of business, we may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We believe the ultimate resolution of any such current proceeding will not have a material adverse effect on our continued financial position, results of operations or cash flows, except as otherwise set forth below.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.